| Literature DB >> 34336613 |
Anita Marliana1,2, Ismail Setyopranoto1,2, Indarwati Setyaningsih1,2, Sholahuddin Rhatomy3,2.
Abstract
CONTEXT: Radiofrequency therapy is a medical procedure mainly used to reduce pain with a low complication rate (less than 1%), ease of application, and low cost. This review's objective was to (1) evaluate the pulsed radiofrequency (PRF) effectiveness in treating radicular pain and (2) assess the PRF procedure's safety in managing radicular pain in lumbar herniated nucleus pulposus (HNP).Entities:
Keywords: Hernia Nucleus Pulposus; Lumbar; Pulsed Radiofrequency; Radicular Pain
Year: 2021 PMID: 34336613 PMCID: PMC8314080 DOI: 10.5812/aapm.111420
Source DB: PubMed Journal: Anesth Pain Med ISSN: 2228-7523
Figure 1.The flowchart of the study selection process
Characteristics of Each Study
| Main Author (Year) | Country | Sample Size | Male: Female | Age, Mean ± SD | Duration of Pain, mo | Measurement of Clinical Outcomes | Level of Dominant HNP | Previous Pain Score, Mean ± SD | Quality of the Study (OCEBM) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||
|
| United States of America | 76 | 45:31 | 39 | 55.1 ± 14.3 | 53.8 ± 14 | > 6 | VAS | L5-S1 | 7.8 ± 1,6 | 7,1 ± 1,9 | 2 |
|
| South Korea | 62 | 11:20 | 10:21 | 65.97 ± 7.25 | 65.16 ± 8.96 | ≥ 3 | NRS; ODI | L5 | 7.39 ± 0.37 | 7.00 ± 0.43 | 2 |
|
| Canada | 31 | 10:6 | 8:7 | 57 (35 - 83) | 57 (35 - 83) | ≥ 4 | VAS | L5-S1 | not reported | not reported | 2 |
|
| South Korea | 18 | Not reported | Not reported | 54.3 ± 12.1 | 50.8 ± 12.7 | 5 | VAS; ODI | L5-S1 | 5.3 ± 1.2 | 4.9 ± 0.8 | 2 |
|
| Egypt | 90 | 59:31 | 45 | 37.5 ± 9 | 39.3 ± 8.8 | > 3 | VAS | L5-S1 | 7.53 ± 0.5 | 7.5 ± 0.5 | 2 |
|
| India | 50 | 9:16 | 13:12 | 41.92 ± 14.53 | 41.4 ± 10.64 | > 3 | VAS; ODI | L5-S1 | 8.24 ± 0.96 | 8.12 ± 1.05 | 2 |
Abbreviations: ODI, Oswestry disability index; Oxford Center for Evidence-Based Medicine; SD, standard deviation; OCEBM, VAS, Visual Analog scale.
Parameters of the Intervention Procedure, Outcome, Side Effects, and Limitations of Each Study
| Author (Year) | Therapeutic Target | Intervention Parameter | Control Group | Follow up | Result | Adverse Effect | Result of the Study | Limitation | |
|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||
|
| DRG | 42°C, 120 seconds | PRF + CRF | Eight weeks; eight months | Significant compared to the control group | not reported | not reported | 70% of the PRF group patients and 82% of the PRF + CRF group patients had a reduced pain intensity in the second month. The analgesic response was 3.18 months (± 2.81) in the PRF group and 4.39 months (± 3.50) in the PRF + CRF group. The chances of success for both groups were close to 50% in the third month. After eight months, most of the patients experienced no improvement in pain. There were no statistical differences between the PRF group and the PRF + CRF group. | Short-term evaluations were not reported; side effects were not reported. |
|
| DRG | 42°C, 120 seconds | Sham (needle placement) | Four weeks; eight weeks; 12 weeks | Significant compared to the control group | Not Significant compared to the control group | No side effect | The number of patients with successful treatment outcomes was higher in the PRF group in the second (P = 0.032) and third months (P = 0.018). No significant differences were observed regarding the secondary outcome variable (ODI) between the two groups. | Long-term evaluations were not reported. |
|
| DRG | 42°C, 120 seconds | Sham (needle placement) | 24 hours; one week; Four weeks; eight weeks; 12 weeks | Not Significant compared to the control group | Not Significant compared to the control group | No side effect | The differences in VAS and ODI reduction in the PRF groups were not significant in the fourth week and the third month compared to the placebo (oral analgesic drug). Six out of 16 subjects in the PRF group and three out of 15 subjects in the control group experienced a VAS reduction of > 50%. There were no PRF side effects. | Small sample size; no initial VAS data was included; long term evaluation was not reported. |
|
| DRG | 42°C, 240 seconds | TFESI (dexamethasone 5 mg | Two weeks; Four weeks; eight weeks; 12 weeks | Not Significant compared to the control group | Not Significant compared to the control group | increasing of radicular pain (n = 1) | The difference in VAS reduction, ODI in the PRF group was not statistically significant compared to the control group (TFESI of dexamethasone 5 mg) | Small sample size; low baseline VAS; long term evaluations were not reported. |
|
| DRG | 42°C, 120 seconds | TFESI (methylprednisolone 2 mg) | One week; Four weeks; eight weeks; 12 weeks | Significant compared to the control group | Significant compared to control group | not reported | The difference in VAS reduction, ODI (dorsal lumbar root ganglion) was more significant in the PRF group than in the control group (transforaminal epidural injection of methylprednisolone steroid 24 mg) up to three months of follow-up in lumbar HNP patients. | Long-term evaluations were not reported; side effects were not reported |
|
| DRG | 42°C, 180 seconds | TFESI | Two weeks; Four weeks; Eight weeks; 12 weeks; 24 weeks | Significant compared to the control group | Significant compared to control group | not reported | The difference in VAS reduction, ODI (dorsal lumbar root ganglion) was more significant in the PRF group than in the control group (TFESI injection) up to 24- week evaluation. | Long-term evaluations were not reported; side effects were not reported. |
Abbreviations: CRF, continuous radiofrequency; DRG, dorsal root ganglion; TFESI, transforaminal epidural steroid injection.
Figure 2.Summary of risk of bias: an overview of each risk of bias item for each included study
Figure 3.Summary of risk of bias: an overview of the assessment of each risk of bias item for each included study
Figure 4.The funnel plot of the PRF effect on radicular pain in lumbar HNP
Figure 5.The forest plot of differences in pain score reduction between the PRF group and the control group: (A) before the treatment, as well as (B) four, (C) eight, and (D) twelve weeks after the treatment